Single-Dose Synthetic Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type II Major Depressive Episodes: A Nonrandomized Open-Label Trial.

JAMA Psychiatry · 2024 · PMC10701666 · PMID 38055270

Europe PMC DOI

hedged sentence

0.0490

closest p · 1.0× alpha

0.0490

boldest claim

The sentences

an overall trendP = .049actually significant

Additional Secondary Outcome Measures: Mania Symptoms, Suicidal Ideation, Quality of Life The repeated-measures ANOVA on YMRS scores at the 4 time points suggested an overall trend for a reduced mania symptom severity over time ( F 3,42 = 2.85; P = .049).

also in 909 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.